Lilly 2005 Sales Growth Will Rest On Strength Of New Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the eight products that Lilly has launched since November 2001 are projected to account for 20% of total sales, CFO Golden tells analysts. Lilly expects Yentreve (duloxetine) to win FDA approval for stress urinary incontinence in the first half of 2005.
You may also be interested in...
Lilly Withdraws Yentreve NDA One Day Ahead Of Expected Negative Review
Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.
Lilly Withdraws Yentreve NDA One Day Ahead Of Expected Negative Review
Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.
Yentreve Launch Will Be Slowed By Poor Patient Awareness, Lilly Predicts
Lilly expects its launch of Yentreve (duloxetine) will be slowed by a lack of patient awareness about the stress urinary incontinence treatment